This morning, Compass Pathways shared a readout from the first of two Phase 3 trials investigating its synthetic psilocybin candidate, COMP360, in treatment-resistant depression (TRD). That makes it the first Phase 3 study of a classical psychedelic to print data.The company reports that the 25mg COMP360 psilocybin arm separated from placebo, with a “statistically significant and clinically…
